

## Nepal Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Nepal					
<b>2. Grant number:</b> 1821-NPL-12a-X / 14-NPL-08c-Y / 18-NPL-25a-Y					
<b>3. Date of Decision Letter:</b> 5 March 2018					
<b>4. Date of the Partnership Framework Agreement:</b> 22 August 2014					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV10), 2 doses per vial, LIQUID; Pneumococcal (PCV10), 4 doses per vial, LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2014 - 2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)					
	2014-2017	2018	2019	2020	2021
Programme Budget (US\$)	25,809,850 <sup>2</sup>	5,581,000	6,439,000	6,766,500	6,960,500
Total (US\$) <sup>3</sup>	51,556,850				
<b>10. Vaccine introduction/ Product Switch grant (in US\$):</b> a VIG of US\$551,000 was disbursed in February 2014. A Product Switch Grant of US\$ 160,636 was approved in February 2018 and will be disbursed.					
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>4</sup>					
Type of supplies to be purchased with Gavi funds in each year	2014-2017	2018			
Number of Pneumococcal vaccines doses		1,662,000			
Annual Amounts (US\$)	25,809,850 <sup>5</sup>	5,581,000			
<b>12. Procurement agency:</b> UNICEF The Country shall release its co-financing payments each year to UNICEF.					
<b>13. Self-procurement:</b> Not applicable					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

**14. Co-financing obligations:** Reference code: 1821-NPL-12a-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	116,000	128,800	130,400	134,000
Value of vaccine doses (US\$)	353,467			
Total co-financing payments (US\$) (including freight)	356,000	394,000	399,500	411,000

**15. Operational support for campaigns:** Not applicable

**16. Additional reporting requirements:**

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

**17. Financial clarifications:** Not applicable

**18. Other conditions:** Not applicable

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
5 March 2018